RTI 336 | CAS#204069-50-1 | DAT inhibitor

MedKoo Cat#: 461504 | Name: RTI 336

Description:

WARNING: This product is for research use only, not for human or veterinary use.

RTI 336 is a chronic brain dopamine transporter (DAT) inhibitor.

Chemical Structure

RTI 336

CAS#204069-50-1

Theoretical Analysis

MedKoo Cat#: 461504

Name: RTI 336

CAS#: 204069-50-1

Chemical Formula: C24H26Cl2N2O

Exact Mass: 428.1422

Molecular Weight: 429.38

Elemental Analysis: C, 67.13; H, 6.10; Cl, 16.51; N, 6.52; O, 3.73

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

RTI 336; RTI336; RTI-336;

IUPAC/Chemical Name

5-((1R,2S,3S,5S)-3-(4-chlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octan-2-yl)-3-(p-tolyl)isoxazole hydrochloride

InChi Key

IZMZEMAKFSYLMD-SXBQIKTFSA-N

InChi Code

InChI=1S/C24H25ClN2O.ClH/c1-15-3-5-17(6-4-15)21-14-23(28-26-21)24-20(16-7-9-18(25)10-8-16)13-19-11-12-22(24)27(19)2;/h3-10,14,19-20,22,24H,11-13H2,1-2H3;1H/t19-,20+,22+,24-;/m0./s1

SMILES Code

CC1=CC=C(C2=NOC([C@@H]3[C@@](N4C)([H])CC[C@@]4([H])C[C@@H]3C5=CC=C(Cl)C=C5)=C2)C=C1.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 429.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Andersen ML, Sawyer EK, Carroll FI, Howell LL. Influence of chronic dopamine transporter inhibition by RTI-336 on motor behavior, sleep, and hormone levels in rhesus monkeys. Exp Clin Psychopharmacol. 2012 Apr;20(2):77-83. doi: 10.1037/a0026034. Epub 2011 Oct 24. PubMed PMID: 22023668; PubMed Central PMCID: PMC3302935. 2: Czoty PW, Martelle JL, Carroll FI, Nader MA. Lower reinforcing strength of the phenyltropane cocaine analogs RTI-336 and RTI-177 compared to cocaine in nonhuman primates. Pharmacol Biochem Behav. 2010 Sep;96(3):274-8. doi: 10.1016/j.pbb.2010.05.017. Epub 2010 May 24. PubMed PMID: 20580733; PubMed Central PMCID: PMC2907452. 3: Hiranita T, Wilkinson DS, Hong WC, Zou MF, Kopajtic TA, Soto PL, Lupica CR, Newman AH, Katz JL. 2-isoxazol-3-phenyltropane derivatives of cocaine: molecular and atypical system effects at the dopamine transporter. J Pharmacol Exp Ther. 2014 May;349(2):297-309. doi: 10.1124/jpet.113.212738. Epub 2014 Feb 11. Erratum in: J Pharmacol Exp Ther. 2014 Jun 1;349(3):534. PubMed PMID: 24518035; PubMed Central PMCID: PMC3989806. 4: Haile CN, Zhang XY, Carroll FI, Kosten TA. Cocaine self-administration and locomotor activity are altered in Lewis and F344 inbred rats by RTI 336, a 3-phenyltropane analog that binds to the dopamine transporter. Brain Res. 2005 Sep 7;1055(1-2):186-95. PubMed PMID: 16095575. 5: Carroll FI, Howard JL, Howell LL, Fox BS, Kuhar MJ. Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse. AAPS J. 2006 Mar 24;8(1):E196-203. Review. PubMed PMID: 16584128; PubMed Central PMCID: PMC2751440. 6: Carroll FI, Kosten TR, Buda JJ, Wang L, Walters BB. A Double-Blind, Placebo-Controlled Trial Demonstrating the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336. Front Pharmacol. 2018 Jul 10;9:712. doi: 10.3389/fphar.2018.00712. eCollection 2018. PubMed PMID: 30042675; PubMed Central PMCID: PMC6048956. 7: Howell LL, Carroll FI, Votaw JR, Goodman MM, Kimmel HL. Effects of combined dopamine and serotonin transporter inhibitors on cocaine self-administration in rhesus monkeys. J Pharmacol Exp Ther. 2007 Feb;320(2):757-65. Epub 2006 Nov 14. PubMed PMID: 17105829. 8: Carroll FI, Fox BS, Kuhar MJ, Howard JL, Pollard GT, Schenk S. Effects of dopamine transporter selective 3-phenyltropane analogs on locomotor activity, drug discrimination, and cocaine self-administration after oral administration. Eur J Pharmacol. 2006 Dec 28;553(1-3):149-56. Epub 2006 Sep 23. PubMed PMID: 17067572.